Disulfiram metabolite Cu(DDC)2 enhances radionuclide uptake in vivo revealing insights into tumoural ablation resistance.

Saved in:
Bibliographic Details
Title: Disulfiram metabolite Cu(DDC)2 enhances radionuclide uptake in vivo revealing insights into tumoural ablation resistance.
Authors: Brookes K; Department of Metabolism and Systems Science, College of Medicine and Health, University of Birmingham, Birmingham, UK., Fear JS; Department of Metabolism and Systems Science, College of Medicine and Health, University of Birmingham, Birmingham, UK., Thornton CEM; Department of Metabolism and Systems Science, College of Medicine and Health, University of Birmingham, Birmingham, UK., Zha L; Department of Metabolism and Systems Science, College of Medicine and Health, University of Birmingham, Birmingham, UK., Kim J; School of Biomedical Engineering & Imaging Sciences, King's College London, London, UK., Small B; Research Institute in Healthcare Science, Faculty of Science and Engineering, University of Wolverhampton, Wolverhampton, UK; Disulfican Ltd, University of Wolverhampton Science Park, Wolverhampton, UK., Wongsanit S; Department of Metabolism and Systems Science, College of Medicine and Health, University of Birmingham, Birmingham, UK., Nieto HR; Department of Metabolism and Systems Science, College of Medicine and Health, University of Birmingham, Birmingham, UK., Adcock H; School of Chemistry, University of Birmingham, Birmingham, UK., Jones A; School of Biomedical Engineering & Imaging Sciences, King's College London, London, UK., Pham TT; School of Biomedical Engineering & Imaging Sciences, King's College London, London, UK., Bottegoni G; Institute of Clinical Sciences, University of Birmingham, Birmingham, UK; Università degli Studi di Urbino Carlo Bo, Urbino, Italy., Cox LR; School of Chemistry, University of Birmingham, Birmingham, UK., Kannappan V; Research Institute in Healthcare Science, Faculty of Science and Engineering, University of Wolverhampton, Wolverhampton, UK; Disulfican Ltd, University of Wolverhampton Science Park, Wolverhampton, UK., Wang W; Research Institute in Healthcare Science, Faculty of Science and Engineering, University of Wolverhampton, Wolverhampton, UK; Disulfican Ltd, University of Wolverhampton Science Park, Wolverhampton, UK., Gorvin CM; Department of Metabolism and Systems Science, College of Medicine and Health, University of Birmingham, Birmingham, UK., Stover DG; Division of Endocrinology, Diabetes, and Metabolism and Cancer Biology Program, The Ohio State University College of Medicine and Comprehensive Cancer Center, Columbus, OH, USA., Spitzweg C; Department of Internal Medicine IV, University Hospital of Munich, LMU Munich, Munich, Germany; Division Endocrinology, Diabetes, Metabolism and Nutrition, Mayo Clinic, Rochester, MN, USA., Jhiang S; Division of Endocrinology, Diabetes, and Metabolism and Cancer Biology Program, The Ohio State University College of Medicine and Comprehensive Cancer Center, Columbus, OH, USA., Ringel MD; Division of Endocrinology, Diabetes, and Metabolism and Cancer Biology Program, The Ohio State University College of Medicine and Comprehensive Cancer Center, Columbus, OH, USA., Campbell MJ; Division of Cancer Biology, Cedars Sinai Cancer, Los Angeles, USA., Sunassee K; School of Biomedical Engineering & Imaging Sciences, King's College London, London, UK., Blower PJ; School of Biomedical Engineering & Imaging Sciences, King's College London, London, UK., Boelaert K; Department of Applied Health Sciences, College of Medicine and Health, University of Birmingham, Birmingham, UK., Smith VE; Department of Applied Health Sciences, College of Medicine and Health, University of Birmingham, Birmingham, UK., Read ML; Department of Metabolism and Systems Science, College of Medicine and Health, University of Birmingham, Birmingham, UK. Electronic address: m.l.read.20@bham.ac.uk., McCabe CJ; Department of Metabolism and Systems Science, College of Medicine and Health, University of Birmingham, Birmingham, UK. Electronic address: mccabcjz@bham.ac.uk.
Source: EBioMedicine [EBioMedicine] 2026 Mar; Vol. 125, pp. 106165. Date of Electronic Publication: 2026 Feb 11.
Publication Type: Journal Article
Journal Info: Publisher: Elsevier B.V Country of Publication: Netherlands NLM ID: 101647039 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2352-3964 (Electronic) Linking ISSN: 23523964 NLM ISO Abbreviation: EBioMedicine Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2352-3964
DOI:10.1016/j.ebiom.2026.106165